RxDoctor Payments Data

Kennon Miller, MD

Urology · E Providence, RINPI 1689786725

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,695 of the $2,698 with a category attached, or 62.8%. Boston Scientific accounts for 66.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,109 and has fallen 98.3% since, to $36 in 2025. That places this record below the midpoint for urology clinicians in RI, where the typical reported total is $2,349.

$2,698in general payments, 2019–2025

Across 52 payments — averaging $51.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Coloplast$494
  • Teleflex LLC$146
  • Pfizer$72
  • Dornier Medtech America, Inc$55
  • Astellas Pharma US Inc$46
  • plus $93 from 4 others

What the payments were for

  • Travel & lodging$88133%
  • Food & beverage$1,69563%
  • Education$1214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,698 in reported general payments places this provider in the 50th percentile of 55 urology providers in Rhode Island.

See all urology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$66,917
Medicare patients
178
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron35$26,313
MyrbetriqMirabegron26$11,630
Oxybutynin Chloride ErOxybutynin Chloride64$1,893
Tamsulosin Hcl94$1,720
Tolterodine Tartrate ErTolterodine Tartrate18$1,094
Solifenacin Succinate17$803
Trospium Chloride11$665
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim90$641
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$569
Oxybutynin Chloride33$566
Cephalexin78$494
Finasteride29$412
Alfuzosin Hcl ErAlfuzosin Hcl13$385
Ciprofloxacin Hcl28$189
Nystatin11$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$46$11,63026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 55 urology providers in Rhode Island.

Other urology in E Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →